BB Biotech AG - Asset Resilience Ratio
BB Biotech AG (BION) has an Asset Resilience Ratio of 0.05% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check BB Biotech AG (BION) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how BB Biotech AG's Asset Resilience Ratio has changed over time. See BION equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down BB Biotech AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BION market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0% |
| Short-term Investments | CHF1.21 Million | 0.05% |
| Total Liquid Assets | CHF1.21 Million | 0.05% |
Asset Resilience Insights
- Limited Liquidity: BB Biotech AG maintains only 0.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
BB Biotech AG Industry Peers by Asset Resilience Ratio
Compare BB Biotech AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
Annual Asset Resilience Ratio for BB Biotech AG (2012–2025)
The table below shows the annual Asset Resilience Ratio data for BB Biotech AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.04% | CHF1.20 Million ≈ $1.51 Million |
CHF2.79 Billion ≈ $3.52 Billion |
-99.95pp |
| 2024-12-31 | 100.00% | CHF2.41 Billion ≈ $3.04 Billion |
CHF2.41 Billion ≈ $3.04 Billion |
+0.07pp |
| 2023-12-31 | 99.93% | CHF2.64 Billion ≈ $3.33 Billion |
CHF2.64 Billion ≈ $3.33 Billion |
+0.46pp |
| 2022-12-31 | 99.47% | CHF3.04 Billion ≈ $3.84 Billion |
CHF3.05 Billion ≈ $3.86 Billion |
-0.47pp |
| 2021-12-31 | 99.94% | CHF3.64 Billion ≈ $4.60 Billion |
CHF3.64 Billion ≈ $4.61 Billion |
+0.03pp |
| 2020-12-31 | 99.90% | CHF3.96 Billion ≈ $5.01 Billion |
CHF3.96 Billion ≈ $5.01 Billion |
+0.04pp |
| 2019-12-31 | 99.86% | CHF3.55 Billion ≈ $4.49 Billion |
CHF3.55 Billion ≈ $4.49 Billion |
-0.11pp |
| 2018-12-31 | 99.97% | CHF3.09 Billion ≈ $3.90 Billion |
CHF3.09 Billion ≈ $3.90 Billion |
+0.06pp |
| 2017-12-31 | 99.91% | CHF3.63 Billion ≈ $4.60 Billion |
CHF3.64 Billion ≈ $4.60 Billion |
+0.37pp |
| 2016-12-31 | 99.54% | CHF3.21 Billion ≈ $4.06 Billion |
CHF3.23 Billion ≈ $4.08 Billion |
+0.36pp |
| 2015-12-31 | 99.18% | CHF4.11 Billion ≈ $5.20 Billion |
CHF4.14 Billion ≈ $5.24 Billion |
-0.43pp |
| 2014-12-31 | 99.62% | CHF3.52 Billion ≈ $4.45 Billion |
CHF3.53 Billion ≈ $4.47 Billion |
+1.64pp |
| 2013-12-31 | 97.98% | CHF2.17 Billion ≈ $2.74 Billion |
CHF2.21 Billion ≈ $2.80 Billion |
+0.18pp |
| 2012-12-31 | 97.80% | CHF1.34 Billion ≈ $1.70 Billion |
CHF1.37 Billion ≈ $1.74 Billion |
-- |
About BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domicile… Read more